Clebopride

General information

Like alizapride, clebopride is a prokinetic dopamine receptor antagonist that has extrapyramidal effects. These effects were initially overlooked, but a warning was eventually issued in 1988 [ ]. The problem has continued to be reported, the incidence at effective doses probably being as high as 25%.

In a 1991 report on a crossover trial, a third of the participants had to withdraw because of adverse reactions, among which drowsiness, dizziness, tremors, and anxiety were prominent [ ].